Atara Biotherapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ATRA updated stock price target summary. See Atara Biotherapeutics, Inc. (ATRA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA) . Barron's also provides information on historical stock ratings, target prices, Atara Biotherapeutics (NASDAQ: ATRA) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and 11 Mar 2020 Goldman repeated the rating from the previous report, marking ATRA The volatility of the stock on monthly basis is set at 8.97%, while the
Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. CAPS Rating . 23
Atara Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell The high price target for ATRA is $70.00 and the low price target for ATRA is $9.00. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the Based on 4 Wall Street analysts offering stock ratings for Atara Biotherapeutics in the last 3 months (by analysts ranked 0 to 5 stars). All Analysts. Top Analysts The current consensus among 10 polled investment analysts is to Buy stock in Atara Biotherapeutics Inc. This rating has held steady since November, when it Get breaking news and analysis on Atara Biotherapeutics, Inc. (ATRA) stock, price quote and chart, trading and investing tools. Atara Biotherapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ATRA updated stock price target summary.
ATRA: Get the latest Atara Biotherapeutics stock price and detailed information including ATRA news, historical charts and realtime prices.
17 Apr 2015 Furthermore, with ATRA–ATO combinations, chemotherapy may safely be As a single agent, ATRA induced CR rates of 85% in studies by the Shanghai Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E et al. 6 Jan 2020 Atara Bio (ATRA). Source: Shutterstock. Atara Biotherapeutics (NASDAQ:ATRA) is developing novel treatments for patients with cancer,
What are people saying about $ATRA? Stock Ticker for ATRA Unicorn Bay rating for $ATRA is 1.69 out of 5. https://t.co/npCEvFPWAl. March 30th 2020,
Mar 27, 2020 · Find the latest analyst research for Atara Biotherapeutics, Inc. Common Stock (ATRA) at Nasdaq.com. Atara Biotherapeutics, Inc. (ATRA) Quant Ratings | Seeking ... An overall objective rating for Atara Biotherapeutics, Inc. (ATRA) optimized for predictive value. Seeking Alpha's Quant Ratings are generated by comparing over 100 metrics. ATRA Stock Rating and Data | Atara Biotherapeutics ... ATRA stock rating and analysis - Atara Biotherapeutics : a summary of key financial strength and profitability metrics. Home Homepage Membership Levels Membership Data Coverage Complete Stock List Founder's Message The book Value Investing Forum Podcast Free Trial Screeners Atara Biotherapeutics Inc (ATRA) Quote | Morningstar
Based on 4 Wall Street analysts offering stock ratings for Atara Biotherapeutics in the last 3 months (by analysts ranked 0 to 5 stars). All Analysts. Top Analysts
ATRA Stock Price, Forecast & News (Atara Biotherapeutics)
Dec 10, 2019 · Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) today.The company’s shares closed last Monday at $14.67, close to its 52-week low of $10.38. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 7.3% and a 52.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio